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ABSTRACT 
Background: Acute leukemia is a common pediatric cancer. Novel strategies for treatment of acute leukemia 
have been developed, but treatment resistance is remained as the most problematic issue. It is hypothesized 
that the HO-1 gene up-regulation is responsible for tumor resistance to chemotherapy or radiotherapy-
induced apoptosis. The levels of HO-1 expression are related to (GT)n microsatellite polymorphisms in the 
location of its promoter. This study designed to compare allelic frequencies of (GT)n microsatellite 
polymorphisms in HO-1 gene between acute leukemia patients and healthy controls. Indeed, 3-year disease-
free survival was also evaluated. 
Methods: Sixty-three patients with acute leukemia and seventy healthy infants were included in this study. 
We used the medical records of patients to collect information about survival after chemotherapy. The number 
of GT repeats in HO-1 promoter was determined by an ABI 3100 sequencer. 
Results: The HO-1 GT repeats ranged from 14 to 34 with peaks at 27 repeats in both cases and controls. 
Children with longer alleles ((GT)n ≥ 27) had enhanced 3-year survival rate after treatment with 
chemotherapy or radiotherapy (P<0.05).  
Conclusion: Although no significant differences were observed between leukemia patients and controls 
regarding allelic frequency, we found elevated frequency of “LL” genotype in leukemia patients with good 
prognosis and 3-year surveillance. Radiotherapy and chemotherapy might elevate the expression levels of HO-
1 with subsequent increased resistance of leukemia patients to therapy.  
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INTRODUCTION 
   Acute Leukemia is the most common pediatric 
cancer1,2. Despite numerous efforts focused on 
leukemia treatment, this type of disease remains 
one of the greatest challenges in pediatric 
oncology3. Current therapeutic strategies are 
unable to provide long-term remission for 20% of 
children with ALL (25-40% cure rate after relapse)4. 
Some subgroups of infants are likely to be over 
treated and might be healed using less intensive 
regimens which results in reduced toxicity and 
fewer long-term side effects5-7. Response to 
treatments is variable depending on different 
clinical, immunological, cytogenetic/genetic 
characteristics and environmental exposures, which 
are associated with increased risk of leukemia and 
their diverse response to treatment8-12. 
One of the mentioned genetic factors is Heme 
Oxygenase-1 gene (HO-1), located on chromosome 
22. This gene produces an essential enzyme in 
heme catabolism.  It has 2 isozymes, an inducible 
heme oxygenase-1 and a constitutive heme 
oxygenase-213. HMOX1 and HMOX2 belong to the 
heme oxygenase family. Heme Oxygenase (HO) 
gene encodes an enzyme which catalyzes the first 
and rate-limiting steps in oxidative degradation of 
heme to the form of open-chain tetrapyrrole 
biliverdin-IX with final release of carbon dioxide, 
biliverdin and free iron . By now, three isozymes of 
mammalian HO have been identified, in which HO-1 
variant is the only inducible isozyme with 
expression in different normal and neoplastic cells. 
HO-1 expression in malignant tissues is higher than 
its surrounding healthy tissues which could be up 
regulated by different stimuli and oxidative stresses 
such as radiotherapy, chemotherapy and 
photodynamic therapies14-20.  
HO-1 is involved in pathogenesis of acute leukemia 
patients and their resistance to treatment8-11. 
Expression of HO-1 has the protective and anti-
apoptotic effects through its active biological 
products21,22. As a result, it's possible that the 
upregulation of HO-1 is responsible for increasing 
tumor resistance to chemotherapy or 
radiotherapy23, 24. However, HO-1 expression level is 
dependent to its polymorphisms and fluctuates 
between individuals, quantitatively25, 26. 
GT repeats in HO-1 gene promoter modulate 
transcription of HO-1 gene. The dinucleotide 
sequence can adversely affect the basal promoter 
activity27-30. GT repeats ranged between 12 - 40 
base pairs. This range can be divided into short “S” 
and long “L” alleles although there is not an exact 
cut-off to separate two alleles16,31,32. Moreover, 
some surveys revealed higher prevalence of "S" 
allele in renal cell carcinoma, pancreatic cancer, 
gastric cancer and gastric adenocarcinoma33. 
Paradoxically, patients with squamous cell 
carcinoma and lung adenocarcinoma often carry “L” 
allele16,31,34-37. Some studies revealed that HO-1 
targeting with either pegylated zinc protoporphyrin 
(PEG-ZnPP) or styrene maleicacid-micelle–
encapsulated ZnPP (SMAZnPP) results in growth 
inhibition in cancer cells with subsequent increased 
sensitivity to radiotherapy and chemotherapy22,38-40.  
Despite advent of novel strategies for treatment of 
acute leukemia, resistance to treatment is the 
greatest concern until now. HO-1 over expression 
provides cytoprotective and antiapoptotic effects 
on malignant cells against radiotherapy and 
chemotherapy. Although the role of HO-1 in AML 
and CML cell lines has been studied, the distribution 
of allele frequency in leukemia and its association 
with resistance to treatment and survival remains 
unveiled10. This study was designed to compare the 
allelic frequencies of genetic variants in the 
promoter of HO-1 among patients suffering from 
acute leukemia compared with healthy controls. 
The relationship between GT repeats and patient’s 
3-year and 5-year survival was also assessed.  
 
MATERIALS AND METHODS  
Patient selection 
This is a controlled, cross-sectional study that 
included 63 patients with acute leukemia admitted 
to Seyed-al-Shohada Hospital, Isfahan from 2006 to 
2009. The control group consisted of 54 gender and 
age-matched healthy children. Our data about 
survival after chemotherapy and bone graft were 
gathered from patients’ medical records. DNA was 
extracted from bone marrow samples of the 
patients. Genomic DNA was extracted through 
QIAamp DNA blood mini kit (QIAGEN, USA) 
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according to the manufacturer’s instruction. The 
study protocol was approved by the Ethics Board of 
Isfahan University of Medical Sciences. 
 
Heme oxygenase-1 genotyping 
The HO-1 microsatellite was amplified through PCR 
using a 5'-FAM-labeled forward primer 
(AGAGCCTGCAGCTTCTCAGA) and a 3'-unlabelled 
reverse primer (GTCCTATGGCCAGACTTTGT), in 30 
cycles (94°C for 30 seconds, 60°C for 30 seconds, 
and 72°C for 30 seconds) and final extension at 72°C 
for 5 minutes by thermo cycler (Eppendorf 
Mastercycler EP Gradient, USA). Labeled PCR 
products were compared with a standard size 
marker GenoTypeTM TAMRA DNA ladder (size range 
50–500 bp) (Gibco-BRL, Paisley, Scotland, UK). 
Number of GT repeats was determined with an ABI 
3100 sequencer (Applied Biosystems, USA), using 
GeneMarker V1.97 software (Softgenetics, USA). 
Selected samples were sequenced by ABI 3100 
sequencer (Applied Biosystems, USA).  
 
Statistical analysis 
Statistical analyses were performed using SPSS 16.0. 
Chi-square test was used for categorical variables. 
Three-year survival was compared with allelic 
frequencies of HO-1 polymorphism. Differences in 
alleli c frequency of HO-1 promoter were compared 
between leukemia patients and controls. Difference 
of data with P< 0.05 was considered as a significant.  
 
RESULTS 
   Demographic characteristics of patients including 
age and sex are shown in Table 1. Frequency 
distribution of age and sex was not significantly 
different between studied groups. Patients whose 
data were incomplete were excluded from the 
study. 
 
 
Table1. Demographic characteristics of patients (age and sex) 
 
The HO-1 genotyping process for 63 cases and 54 
healthy controls was performed successfully. The 
alleles frequency of (GT)n microsatellite 
polymorphism of HO -1 gene promoter was found in 
both case and control groups (Figures 1, 2 and 3). 
The GT repeat numbers ranged from 14 to 34, and 
the most prevalent allele in our population was 
(GT)27. Therefore, we divided these alleles into two 
subgroups. (GT)n : short (S) alleles <27 repeats and 
long (L) alleles ≥27 repeats.  Three genotypes (SS, SL 
and LL) were created for the study population. The 
subjects with genotype SS and SL were placed in a 
group identified as "short carrier genotype" and 
those with LL genotype were placed in a group 
identified as "long genotype". 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group  
 
Case control P-value 
Age (years)  Mean ±SD  5.93 ±0.63           
 
4.87±0.26 >0.05       
 Gender (%)                                                        F  59.5 46.2 >0.05       
 
M  40.5 53.8 
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Figure 1: Frequency distributions of (GT) repeats in all participants (n=117) 
 
 
 
Figure 2: Frequency distributions of (GT) repeats in leukemia patient (n=56) 
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Figure 3: Frequency distributions of (GT) repeats in control group (n=61) 
 
There was no significant difference in the frequency 
of genotypes between leukemia patients and 
controls (P= 0.629) (Table 2). The "long genotype" 
was more frequent in leukemia patients with better 
vs. worse 3-year surveillance (P< 0.05)(Table 3). 
Furthermore, there was no significant difference in 
hepatomegaly, splenomegaly and CSF metastasis in 
two genotype groups (P≥0.05) (Table 4).   
 
Table 2. Genotype* distribution in case and control groups  
 Genotypes P-value 
 LL LS SS 
 
 
 
0.629 Case 33.3% 47.6% 19% 
Control 33.3% 40.7% 25.9% 
* (GT)n < 27 Repeats: S allele,  (GT)n ≥ 27 Repeats: L allele, SS: Homozygote for Short Allele, LL: Homozygote for Long Allele, LS: Heterozygote 
Person 
Table 3. Genotype* distribution for leukemia patients according to 3-and 5-year survival, respectively 
  Genotype  P-value 
  S carrier LL  
3-year survival rate     
 Yes 38.8% 30.5% 0.043 
 No  27.7% 2.7%  
5-year survival rate     
 Yes 39.3% 21.2% 0.371 
 No 30.3% 9.0%  
 (GT)n < 27 Repeats: S allele,  (GT)n ≥ 27 Repeats: L allele, SS: Homozygote for Short Allele, LL: Homozygote for Long Allele, LS: Heterozygote Person 
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Table 4. Genotype* distribution of leukemic regarding hepatomegaly, splenomegaly and CSF metastasis 
  Genotypes    P-value 
 
 
 S carrier LL  
Hepatomegaly 
 
(+) 
(-) 
 
21.0% 
50.0% 
15.85 
13.1% 
0.142 
Splenomegaly 
 
(+) 
(-) 
 
40.5% 
29.7% 
16.2% 
13.5% 
0.571 
CSF Metastasis 
 
(+) 
(-) 
2.9% 
67.6% 
0.0% 
29.4% 
0.706 
* S carrier: a person who is carrier for S allele, LL: Homozygote for L allele, CSF Metastasis: Metastasis to Cerebrospinal fluids (CSF)  
DISCUSSION 
   In this study, we investigated polymorphic (GT)n 
repeats in HO-1 promoter region in patients 
suffering from leukemia. In addition, we 
investigated the association between allelic 
frequency and patients’ 3-year surveillance. We 
found no relationship between frequency 
distribution of (GT)n repeats and leukemia 
incidence. We have observed that patients carrying 
“LL” allele had significantly better 3-year survival. 
Five-year survival was slightly better in carriers of 
“LL” allele although this difference was not 
statistically significant. Moreover, we studied 
genotype distribution among patients considering 
hepatomegaly, splenomegaly and CSF metastasis 
(Table 4), which revealed no relationship between 
(GT)n repeats in HO-1 promoter and clinical 
features of patients.   
HO-1 gene is induced in response to oxidative stress 
such as chemotherapy and radiotherapy41. The 
basal and induced levels of HO-1 gene expression 
are different in each individual. The polymorphism 
length of HO-1, influences the level of gene 
transcription. Excessive GT repeats reduced 
promoter activity, while short GT alleles led to 
higher levels of HO-1 expression with further anti-
apoptotic effects. Our results suggest that “SS” and 
“SL” genotypes make tumors more resistant to 
anticancer therapy in acute leukemia.  
HO-1 considered as a “friend” which supports 
normal tissues against carcinogen-induced 
invasion42,43. Nevertheless, during the neoplastic 
development, HO-1 turns into a “false friend” and 
facilitate tumor development. HO-1 over expression 
in CML tumor cells increases its viability through 
apoptosis inhibition. 
Meyerhof et al. have treated CML cells by zinc-(II)-
deuteroporphyrin-IX, inhibitor of HO-1 and hemin, 
inducer of an HO-1. Parallel usage of HO-1 inhibitors 
and inducers, decreases and increases CML cells 
viability in stress oxidative environment, 
respectively. Also, it has been apparent that HO-1 
reduces sensitivity of cancer cells to chemotherapy 
and radiotherapy22,44.  
The length polymorphism of GT repeats in HO-1 
gene promoter had various impacts in different 
disease states. Chang et al. reported an increased 
risk of oral squamous cell carcinoma in patients 
with more than 31 GT-repeats45. Moreover, some 
surveys revealed a higher frequency of "S" allele in 
renal cell carcinoma, pancreatic cancer, gastric 
cancer, gastric adenocarcinoma, lymphoma and 
Kaposi sarcoma. In this study, the frequency of “S” 
alleles and “L” alleles were equal in both leukemia 
patients and control groups. 
This study is the first to investigate HO-1 gene 
promoter polymorphism and surveillance (3 years) 
in leukemia patients. Although we found no 
significant differences between leukemia patients 
and control groups regarding short (GT) n repeat 
alleles in HO-1 promoter, higher frequency of “LL” 
genotype in leukemia patients with positive 3-year 
surveillance was found. Indeed, LL genotype in 
leukemia patients was associated with slightly 
better 5-year surveillance.  
Oxidative stress conditions such as radiotherapy 
and chemotherapy lead to additional expression of 
HO-1 gene41. These data supports the idea that 
higher levels of HO-1 gene expression, associated 
with “SS” and “SL” genotype, might play an 
important role in elevated resistance of leukemia 
patients to chemotherapy or radiotherapy. 
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CONCLUSION 
   Modification of HO-1 expression level might have 
positive effect on the prognosis of leukemia 
patients under treatment. Further studies are 
required to determine the impact of HO-1 
genotype in patients with acute leukemia. 
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